4:01 PM
 | 
Nov 13, 2017
 |  BC Extra  |  Financial News

Immuno-oncology play Arcus raises $107M

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV.

New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital and Leerink Partners also participated, along with existing investors The Column Group, Foresite Capital, Invus Opportunities, DROIA, Celgene...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >